Key Details
Price
$15.69Last Dividend
$0.10Annual ROE
21.78%Beta
0.31Events Calendar
Next earnings date:
Jan 30, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
May 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
July 30, 2024Next split:
N/ARecent split:
Nov 05, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
RDY has a solid position in the worldwide generics market because of its extensive range of generic drugs. Their work to improve their biosimilars collection is impressive.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. has announced that it is launching Toripalimab in India.
Dr. Reddy's Laboratories Limited (NYSE:RDY) will hold its Q2 2025 Earnings Conference Call on November 5, 2024, at 9:00 AM ET. The call will feature company representatives, including Richa Periwal, the Head of Investor Relations, and Erez Israeli, the CEO. Participants will be in listen-only mode, but there will be a chance to ask questions after the presentation.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's has entered into a voluntary licensing agreement with Gilead Sciences to produce and sell Lenacapavir in India and other nations.
Dr. Reddy's (RDY) is preparing to possibly work with Kainomyx to co-develop a cost-effective anti-malarial medication.
Since my last report, Dr. Reddy's Laboratories stock has increased by 29%, benefiting from new laws and strong business performance. The company maintains a strong competitive edge in the generics pharmaceutical sector, leading to consistently high returns on capital. Recent quarterly data indicates growth in the U.S., Europe, and India, suggesting an intrinsic value of $107 per share.
Erez Israeli from Dr. Reddy's Laboratories mentioned that the company is definitely looking to enter the biologics sector. He noted that although the U.S. is an important market, India and other regions are expected to grow at a quicker pace.
Dr. Reddy's (RDY) has released its first-quarter results for fiscal 2025, showing a mix of outcomes. While earnings fell short of expectations, revenues exceeded estimates due to an increase in global generics sales in North America and India.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
FAQ
- What is the primary business of Dr Reddys Laboratories Limited?
- What is the ticker symbol for Dr Reddys Laboratories Limited?
- Does Dr Reddys Laboratories Limited pay dividends?
- What sector is Dr Reddys Laboratories Limited in?
- What industry is Dr Reddys Laboratories Limited in?
- What country is Dr Reddys Laboratories Limited based in?
- When did Dr Reddys Laboratories Limited go public?
- Is Dr Reddys Laboratories Limited in the S&P 500?
- Is Dr Reddys Laboratories Limited in the NASDAQ 100?
- Is Dr Reddys Laboratories Limited in the Dow Jones?
- When was Dr Reddys Laboratories Limited's last earnings report?
- When does Dr Reddys Laboratories Limited report earnings?